SFDA Grants Breakthrough Designation to "Inplyra" for the Treatment of Patients with Type 3 Gaucher Disease

The Saudi Food and Drug Authority (SFDA) has granted Breakthrough Designation to Inplyra (venglustat), developed by Sanofi, for the treatment of patients aged two years and older with Type 3 Gaucher disease, to be utilized as a long-term treatment to help manage neurological symptoms and maintain systemic stability previously achieved through enzyme replacement therapy.

Gaucher disease Type 3 is classified as a rare genetic lysosomal storage disorder, caused by the abnormal accumulation of specific fats within various body organs and tissues.

Registration Subject to Full Scientific Evaluation

The SFDA emphasizes that this designation allows Inplyra to be submitted and reviewed under the Breakthrough Track, subject to specific regulatory controls and mechanisms. This designation does not constitute marketing authorization of the drug in Saudi Arabia. A final decision regarding registration will be announced following a full technical and scientific evaluation of the complete registration dossier.

SFDA Breakthrough Medicine Program Accelerates Access to Quality Treatments

The Program is designed to fast-track critical treatments for patients facing serious and life-threatening diseases. It targets innovative therapeutics that have successfully completed clinical trials, demonstrating safety, efficacy, and distinct therapeutic benefits. By condensing regulatory timelines, the Program significantly expands available treatment options and enables early access to innovative medicines.

For further information about the Breakthrough Medicine Program, please refer to the guide available on the SFDA website or contact the Drug Sector Designation Office via email at: Designation.Drug@sfda.gov.sa.